Chronic leukemia : an overview / Seema Bhat.

Format:

Video

Author/Creator:

Bhat, Seema, author.

Language:

English

Subjects (All):

Leukemia.

Chronic diseases.

Physical Description:

1 online resource (1 streaming video file (39 min.))

Other Title:

Chronic leukemia

Place of Publication:

London : Henry Stewart Talks, 2024.

System Details:

video file

Contents:

Introduction

Overview

Chronic lymphocytic leukemia (CLL)

Diagnostic criteria (iwCLL 2018)

Differential diagnosis

What about MBL?

MBL management

CLL vs. SLL vs. MBL

Natural history of CLL

CLL presentation

Rai staging (1)

Rai staging (2)

Rai stage is associated with survival

Cytogenetics & fluorescence in situ hybridization (FISH)

FISH testing & hierarchical risk categories (1)

FISH testing & hierarchical risk categories (2)

Complex karyotype

Immune globulin heavy chain (IGHV) mutational status

Survival by IGHVs mutational status

The CLL-IPI score & risk groups

CLL-IPI predicts survival

CLL-IPI predicts time to first treatment

When should testing be done?

Rationale for observation

Randomized to chlorambucil vs. observation

Meta-analysis of randomized trials of observation

Treatment indications: iWCLL 2018 guidelines

Recommended assessments

How to approach selecting initial treatment

Previously untreated CLL

The development of chemoimmunotherapy

Long-term FCR data

Major mechanisms of action of current CLL therapies

The era of targeted agents

NCCN recommendations

Chemoimmunotherapy vs. ibrutinib

Outstanding efficacy

Ibrutinib regimens have improved PFS and OS

FCR vs. IR in IGHV mutated patients

ELEVATE-TN: randomized phase 3

ELEVATE-TN: frontline acalabrutinib ± obinutuzumab vs. chlorambucil + obinutuzumab

SEQUOIA: frontline zanubrutinib vs. bendamustine/rituximab

BTK inhibitor-based treatment

The BCL2 inhibitor venetoclax

CLL14: first-line obinutuzumab + venetoclax or chlorambucil (time limited)

CLL14: MRD negativity

CLL13 - VO in fit patients

OS after VO according to MRD status

Comparison: first line treatment options (1)

Rationale for combining ibrutinib and venetoclax

GLOW Trial: 4-year follow-up from a multicenter, open-label, randomized, phase 3 trial

Phase III UK NCRI study-primary end-point

Comparison: first line treatment options (2)

Choosing between frontline agents

Making progress in treatments for patients with CLL

Health implications of CLL (treated or not)

Thank you.

Notes:

Description based on publisher supplied metadata and other sources.

Retrieved August 20, 2025, from https://doi.org/10.69645/DTTK9496.